drugset
drugset / Trial / NCT05245578

Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects

NCT05245578 ↗

Phase 1 Completed 20 enrolled PharmaEssentia PharmaEssentia Japan K.K. · collab
NaSingle-groupOpen-labelTreatment

Summary

Skin Irritation and Phototoxicity Study of KX01 Ointment 1% in Japanese healthy male subjects

Timeline

Start
2021-11-16
Primary completion
2021-11-22
Completion
2022-01-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirbanibulin Small molecule 1 % Topical

Indications

No indication recorded.